Activating <i>JAK1</i> mutation may predict the sensitivity of JAK-STAT inhibition in hepatocellular carcinomaShuqun Yang(WuXi AppTec (China)), Douglas D. Fang(Pfizer (United States))OncotargetDecember 19, 201510.18632/oncotarget.6684Cited by 49SaveCiteExport RISWatch citationsRelated PapersAntitumor Efficacy of the Dual PI3K/mTOR Inhibitor PF-04691502 in a Human Xenograft Tumor Model Derived from Colorectal Cancer Stem Cells Harboring a PIK3CA Mutation|PLoS ONE|2013|44Discovery of a novel ALK/ROS1/FAK inhibitor, APG-2449, in preclinical non-small cell lung cancer and ovarian cancer models|BMC Cancer|2022|31